Robert Eckel is an Endocrinology/Metabolic physician affiliated with University of Colorado Anschutz Medical Campus. OpenAlex indexes 231 publications with 39,149 citations (h-index 71); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment
Sponsor: University of Colorado, Denver
- Mechanisms Defending Fat Mass in Humans After Lipectomy
Sponsor: University of Colorado, Denver
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
5 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
91.7%PCSK9 Inhibitor36.5%Praluent Pen100%Part D<11 patientsStatin28.8%Rosuvastatin Calcium58%Atorvastatin Calcium42%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
8.3%Biguanide (metformin)8.3%Metformin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
21 NIH research awards on record, funded 1985–2020 per NIH RePORTER. The latest:
- Microglial Lipoprotein Lipase; a novel therapeutic Target for Alzheimer's disease
University of Colorado Denver
FY2020$194,375R21AG061549 - Microglial Lipoprotein Lipase; a novel therapeutic Target for Alzheimer's disease
University of Colorado Denver
FY2019$233,250R21AG061549 - Exploring the role of microglial lipoprotein lipase in remyelination and repair
University of Colorado Denver
FY2019$194,375R21NS102506
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Schulick, MD, MBA
University of Colorado Anschutz Medical Campus
John Rumsfeld, MD, PhD
University of Colorado Anschutz Medical Campus
Marc Bonaca, MD
University of Colorado Anschutz Medical Campus
Satish Garg, MD
University of Colorado Anschutz Medical Campus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”